Hypoglycemic pharmacological treatment of type 2 diabetes: Targeting the endothelium

Molecular and Cellular Endocrinology

Volumn 297, Issue 1-2, 2009, Pages 112-126

  Nathanson, David ^a   Nyström, Thomas ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Endothelial dysfunction; Heart failure; Hypoglycemic pharmacological treatment; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE; VOGLIBOSE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DOPPLER FLOWMETRY; DRUG MEGADOSE; DRUG PROTEIN BINDING; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER TOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ULTRASOUND;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE;

EID: 57649188618     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.11.016     Document Type: Review

References (237)

1. Anderson T.J., Uehata A., Gerhard M.D., Meredith I.T., Knab S., Delagrange D., Lieberman E.H., Ganz P., Creager M.A., Yeung A.C., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26 (1995) 1235-1241
2. Arcaro G., Cretti A., Balzano S., Lechi A., Muggeo M., Bonora E., and Bonadonna R.C. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105 (2002) 576-582
3. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14 (2003) 137-145
4. Asagami T., Abbasi F., Stuelinger M., Lamendola C., McLaughlin T., Cooke J.P., Reaven G.M., and Tsao P.S. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 51 (2002) 843-846
5. Avignon A., Radauceanu A., and Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20 (1997) 1822-1826
6. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., and Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 (2008) 2340-2350
7. Bar R.S., Hoak J.C., and Peacock M.L. Insulin receptors in human endothelial cells: identification and characterization. J. Clin. Endocrinol. Metab. 47 (1978) 699-702
8. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., and Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 717-726
9. Barragan J.M., Eng J., Rodriguez R., and Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am. J. Physiol. 277 (1999) E784-E791
10. Barragan J.M., Rodriguez R.E., and Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am. J. Physiol. 266 (1994) E459-466
11. Barragan J.M., Rodriguez R.E., Eng J., and Blazquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul. Pept. 67 (1996) 63-68
12. Basu A., Charkoudian N., Schrage W., Rizza R.A., Basu R., and Joyner M.J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab. 293 (2007) E1289-1295
13. Båvenholm P.N., and Efendic S. Postprandial hyperglycaemia and vascular damage-the benefits of acarbose. Diab. Vasc. Dis. Res. 3 (2006) 72-79
14. Beckman J.A., Goldfine A.B., Gordon M.B., Garrett L.A., and Creager M.A. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ. Res. 90 (2002) 107-111
15. Bharucha A.E., Charkoudian N., Andrews C.N., Camilleri M., Sletten D., Zinsmeister A.R., and Low P.A. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295 (2008) R874-880
16. Bijlstra P.J., Lutterman J.A., Russel F.G., Thien T., and Smits P. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia 39 (1996) 1083-1090
17. Blonde L., Klein E.J., Han J., Zhang B., Mac S.M., Poon T.H., Taylor K.L., Trautmann M.E., Kim D.D., and Kendall D.M. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. 8 (2006) 436-447
18. Bojanowska E., and Stempniak B. Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regul. Pept. 91 (2000) 75-81
19. Bots M.L., Westerink J., Rabelink T.J., and de Koning E.J. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur. Heart J. 26 (2005) 363-368
20. Bouloumie A., Marumo T., Lafontan M., and Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J. 13 (1999) 1231-1238
21. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
22. Buchanan T.A., Meehan W.P., Jeng Y.Y., Yang D., Chan T.M., Nadler J.L., Scott S., Rude R.K., and Hsueh W.A. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J. Clin. Invest. 96 (1995) 354-360
23. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 11 (2003) 1278-1289
24. Caballero A.E., Arora S., Saouaf R., Lim S.C., Smakowski P., Park J.Y., King G.L., LoGerfo F.W., Horton E.S., and Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48 (1999) 1856-1862
25. Cabou C., Campistron G., Marsollier N., Leloup C., Cruciani-Guglielmacci C., Penicaud L., Drucker D.J., Magnan C., and Burcelin R. Brain GLP-1 regulates arterial blood flow, heart rate and insulin sensitivity. Diabetes 57 (2008) 2577-2587
26. Calles-Escandon J., and Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. 22 (2001) 36-52
27. Calnek D.S., Mazzella L., Roser S., Roman J., and Hart C.M. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 52-57
28. Campia U., Matuskey L.A., and Panza J.A. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113 (2006) 867-875
29. Campia U., Sullivan G., Bryant M.B., Waclawiw M.A., Quon M.J., and Panza J.A. Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H76-82
30. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., Lloyd J.K., and Deanfield J.E. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
31. Chen Z.P., Mitchelhill K.I., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., Power D.A., Ortiz de Montellano P.R., and Kemp B.E. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 443 (1999) 285-289
32. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
33. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003) 486-494
34. Cho D.H., Choi Y.J., Jo S.A., and Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J. Biol. Chem. 279 (2004) 2499-2506
35. Cho M.C., Lee K., Paik S.G., and Yoon D.Y. Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders. PPAR Res. 2008 (2008) 679137
36. Clark M.G., Wallis M.G., Barrett E.J., Vincent M.A., Richards S.M., Clerk L.H., and Rattigan S. Blood flow and muscle metabolism: a focus on insulin action. Am. J. Physiol. Endocrinol. Metab. 284 (2003) E241-258
37. Corgnali M., Piconi L., Ihnat M., and Ceriello A. Evaluation of gliclazide ability to attenuate the hyperglycaemic 'memory' induced by high glucose in isolated human endothelial cells. Diabetes Metab. Res. Rev. 24 (2008) 301-309
38. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., Deanfield J., Drexler H., Gerhard-Herman M., Herrington D., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 39 (2002) 257-265
39. Cosby K., Partovi K.S., Crawford J.H., Patel R.P., Reiter C.D., Martyr S., Yang B.K., Waclawiw M.A., Zalos G., Xu X., et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat. Med. 9 (2003) 1498-1505
40. Cusi K., Consoli A., and DeFronzo R.A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81 (1996) 4059-4067
41. Cusi K., Maezono K., Osman A., Pendergrass M., Patti M.E., Pratipanawatr T., DeFronzo R.A., Kahn C.R., and Mandarino L.J. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest. 105 (2000) 311-320
42. Davis B.J., Xie Z., Viollet B., and Zou M.H. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 55 (2006) 496-505
43. de Aguiar L.G., Bahia L.R., Villela N., Laflor C., Sicuro F., Wiernsperger N., Bottino D., and Bouskela E. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 29 (2006) 1083-1089
44. Desfaits A.C., Serri O., and Renier G. Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. Metabolism 46 (1997) 1150-1156
45. Detaille D., Guigas B., Chauvin C., Batandier C., Fontaine E., Wiernsperger N., and Leverve X. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 54 (2005) 2179-2187
46. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
47. Doshi S.N., Naka K.K., Payne N., Jones C.J., Ashton M., Lewis M.J., and Goodfellow J. Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. Clin. Sci. (Lond.) 101 (2001) 629-635
48. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
49. Du X.L., Edelstein D., Dimmeler S., Ju Q., Sui C., and Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 108 (2001) 1341-1348
50. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., D'Armiento M., D'Andrea F., and Giugliano D. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292 (2004) 1440-1446
51. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., and Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28 (2005) 2345-2351
52. Fard A., Tuck C.H., Donis J.A., Sciacca R., Di Tullio M.R., Wu H.D., Bryant T.A., Chen N.T., Torres-Tamayo M., Ramasamy R., et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2039-2044
53. Fava D., Cassone-Faldetta M., Laurenti O., De Luca O., Ghiselli A., and De Mattia G. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes. Diabet. Med. 19 (2002) 752-757
54. Federici M., Menghini R., Mauriello A., Hribal M.L., Ferrelli F., Lauro D., Sbraccia P., Spagnoli L.G., Sesti G., and Lauro R. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106 (2002) 466-472
55. Federici M., Pandolfi A., De Filippis E.A., Pellegrini G., Menghini R., Lauro D., Cardellini M., Romano M., Sesti G., Lauro R., et al. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 109 (2004) 399-405
56. Feinglos M.N., and Bethel M.A. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am. Heart J. 138 (1999) S346-S352
57. Fernandez M., Triplitt C., Wajcberg E., Sriwijilkamol A.A., Musi N., Cusi K., DeFronzo R., and Cersosimo E. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 31 (2008) 121-127
58. Festa A., D'Agostino Jr. R., Williams K., Karter A.J., Mayer-Davis E.J., Tracy R.P., and Haffner S.M. The relation of body fat mass and distribution to markers of chronic inflammation. Int. J. Obes. Relat. Metab. Disord. 25 (2001) 1407-1415
59. Festa A., Hanley A.J., Tracy R.P., D'Agostino Jr. R., and Haffner S.M. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108 (2003) 1822-1830
60. Fleming I., and Busse R. Signal transduction of eNOS activation. Cardiovasc. Res. 43 (1999) 532-541
61. Forst T., Lubben G., Hohberg C., Kann P., Sachara C., Gottschall V., Friedrich C., Rosskopf R., and Pfutzner A. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 12 (2005) 543-550
62. Frantz S., Calvillo L., Tillmanns J., Elbing I., Dienesch C., Bischoff H., Ertl G., and Bauersachs J. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. FASEB J. 19 (2005) 591-593
63. Furchgott R.F. The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA 276 (1996) 1186-1188
64. Furchgott R.F., and Vanhoutte P.M. Endothelium-derived relaxing and contracting factors. FASEB J. 3 (1989) 2007-2018
65. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
66. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348 (2003) 383-393
67. Gaenzer H., Neumayr G., Marschang P., Sturm W., Lechleitner M., Foger B., Kirchmair R., and Patsch J. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am. J. Cardiol. 89 (2002) 431-434
68. Gallo A., Ceolotto G., Pinton P., Iori E., Murphy E., Rutter G.A., Rizzuto R., Semplicini A., and Avogaro A. Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes 54 (2005) 1123-1131
69. Gardiner S.M., March J.E., Kemp P.A., and Bennett T. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J. Pharmacol. Exp. Ther. 316 (2006) 852-859
70. Gensch C., Clever Y.P., Werner C., Hanhoun M., Bohm M., and Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192 (2007) 67-74
71. Gerstein H.C., Miller M.E., Byington R.P., Goff Jr. D.C., Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm Jr. R.H., et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358 (2008) 2545-2559
72. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., Hanefeld M., Hoogwerf B., Laakso M., Mohan V., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
73. Gilde A.J., van der Lee K.A., Willemsen P.H., Chinetti G., van der Leij F.R., van der Vusse G.J., Staels B., and van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. 92 (2003) 518-524
74. Giugliano D., Marfella R., Coppola L., Verrazzo G., Acampora R., Giunta R., Nappo F., Lucarelli C., and D'Onofrio F. Vascular effects of acute hyperglycemia in humans are reversed by l-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95 (1997) 1783-1790
75. Gladwin M.T., Schechter A.N., Kim-Shapiro D.B., Patel R.P., Hogg N., Shiva S., Cannon III R.O., Kelm M., Wink D.A., Espey M.G., et al. The emerging biology of the nitrite anion. Nat. Chem. Biol. 1 (2005) 308-314
76. Golay A. Metformin and body weight. Int. J. Obes. (Lond.) 32 (2008) 61-72
77. Guigas B., Detaille D., Chauvin C., Batandier C., De Oliveira F., Fontaine E., and Leverve X. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem. J. 382 (2004) 877-884
78. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339 (1998) 229-234
79. Hamdy O., Ledbury S., Mullooly C., Jarema C., Porter S., Ovalle K., Moussa A., Caselli A., Caballero A.E., Economides P.A., et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 26 (2003) 2119-2125
80. Hanefeld M., Cagatay M., Petrowitsch T., Neuser D., Petzinna D., and Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur. Heart J. 25 (2004) 10-16
81. Hanefeld M., Chiasson J.L., Koehler C., Henkel E., Schaper F., and Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35 (2004) 1073-1078
82. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest. 100 (1997) 2153-2157
83. Hawley S.A., Gadalla A.E., Olsen G.S., and Hardie D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51 (2002) 2420-2425
84. Heitzer T., Krohn K., Albers S., and Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 43 (2000) 1435-1438
85. Hetzel J., Balletshofer B., Rittig K., Walcher D., Kratzer W., Hombach V., Haring H.U., Koenig W., and Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1804-1809
86. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil H.A. 10-Year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359 (2008) 1577-1589
87. Holst J.J., Vilsboll T., and Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol. Cell. Endocrinol. 297 (2009) 127-136
88. Holstein A., and Stumvoll M. Contraindications can damage your health-is metformin a case in point?. Diabetologia 48 (2005) 2454-2459
89. Horio T., Suzuki M., Takamisawa I., Suzuki K., Hiuge A., Yoshimasa Y., and Kawano Y. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am. J. Hypertens. 18 (2005) 1626-1630
90. Hsueh W.A., and Law R.E. Insulin signaling in the arterial wall. Am. J. Cardiol. 84 (1999) 21J-24J
91. Huang P.H., Sata M., Nishimatsu H., Sumi M., Hirata Y., and Nagai R. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed. Pharmacother. 62 (2008) 46-52
92. Hwang J., Kleinhenz D.J., Lassegue B., Griendling K.K., Dikalov S., and Hart C.M. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell Physiol. 288 (2005) C899-905
93. Ihlemann N., Rask-Madsen C., Perner A., Dominguez H., Hermann T., Kober L., and Torp-Pedersen C. Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H875-882
94. Janke J., Engeli S., Gorzelniak K., Luft F.C., and Sharma A.M. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res. 10 (2002) 1-5
95. Jansson P.A., Pellme F., Hammarstedt A., Sandqvist M., Brekke H., Caidahl K., Forsberg M., Volkmann R., Carvalho E., Funahashi T., et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J. 17 (2003) 1434-1440
96. Jiang B., Wu L., and Wang R. Sulphonylureas induced vasorelaxation of mouse arteries. Eur. J. Pharmacol. 577 (2007) 124-128
97. Jiang Z.Y., Lin Y.W., Clemont A., Feener E.P., Hein K.D., Igarashi M., Yamauchi T., White M.F., and King G.L. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J. Clin. Invest. 104 (1999) 447-457
98. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., Kravitz B.G., Lachin J.M., O'Neill M.C., Zinman B., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355 (2006) 2427-2443
99. Katakami N., Yamasaki Y., Hayaishi-Okano R., Ohtoshi K., Kaneto H., Matsuhisa M., Kosugi K., and Hori M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia 47 (2004) 1906-1913
100. Katusic Z.S. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role?. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H981-986
101. Kawano H., Motoyama T., Hirashima O., Hirai N., Miyao Y., Sakamoto T., Kugiyama K., Ogawa H., and Yasue H. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J. Am. Coll. Cardiol. 34 (1999) 146-154
102. Kelly A.S., Thelen A.M., Kaiser D.R., Gonzalez-Campoy J.M., and Bank A.J. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc. Med. 12 (2007) 311-318
103. Kieffer T.J., and Habener J.F. The glucagon-like peptides. Endocr. Rev. 20 (1999) 876-913
104. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., and Nathan D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
105. Koya D., and King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 47 (1998) 859-866
106. Laakso M., Edelman S.V., Brechtel G., and Baron A.D. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41 (1992) 1076-1083
107. Langenfeld M.R., Forst T., Hohberg C., Kann P., Lubben G., Konrad T., Fullert S.D., Sachara C., and Pfutzner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111 (2005) 2525-2531
108. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
109. Liu H., Hu Y., Simpson R.W., and Dear A.E. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression. J. Endocrinol. 196 (2008) 57-65
110. Lundman P., Eriksson M., Schenck-Gustafsson K., Karpe F., and Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 96 (1997) 3266-3268
111. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314 (1997) 1512-1515
112. Malmberg K., Ryden L., Wedel H., Birkeland K., Bootsma A., Dickstein K., Efendic S., Fisher M., Hamsten A., Herlitz J., et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur. Heart J. 26 (2005) 650-661
113. Mamputu J.C., and Renier G. Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. J. Diabetes Complications 16 (2002) 284-293
114. Mamputu J.C., and Renier G. Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide. Diabetes Obes. Metab. 6 (2004) 95-103
115. Marfella R., Acampora R., Verrazzo G., Ziccardi P., De Rosa N., Giunta R., and Giugliano D. Metformin improves hemodynamic and rheological responses to l-arginine in NIDDM patients. Diabetes Care 19 (1996) 934-939
116. Marfella R., Quagliaro L., Nappo F., Ceriello A., and Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J. Clin. Invest. 108 (2001) 635-636
117. Martens F.M., Rabelink T.J., op't Roodt J., de Koning E.J., and Visseren F.L. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur. Heart J. 27 (2006) 1605-1609
118. Martens F.M., Visseren F.L., de Koning E.J., and Rabelink T.J. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J. Cardiovasc. Pharmacol. 46 (2005) 773-778
119. Mather K.J., Verma S., and Anderson T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 37 (2001) 1344-1350
120. Matsumoto T., Noguchi E., Ishida K., Kobayashi T., Yamada N., and Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 295 (2008) H1165-1176
121. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino Sr. R.B., Perez A., Provost J.C., and Haffner S.M. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
122. McGuire D.K., Newby L.K., Bhapkar M.V., Moliterno D.J., Hochman J.S., Klein W.W., Weaver W.D., Pfisterer M., Corbalan R., Dellborg M., et al. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am. Heart J. 147 (2004) 246-252
123. Mellbin L.G., Malmberg K., Norhammar A., Wedel H., and Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur. Heart J. 29 (2008) 166-176
124. Mombouli J.V., and Vanhoutte P.M. Endothelial dysfunction: from physiology to therapy. J. Mol. Cell. Cardiol. 31 (1999) 61-74
125. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
126. 2+ but requires phosphorylation by Akt at Ser(1179). J. Biol. Chem. 276 (2001) 30392-30398
127. Montagnani M., Golovchenko I., Kim I., Koh G.Y., Goalstone M.L., Mundhekar A.N., Johansen M., Kucik D.F., Quon M.J., and Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J. Biol. Chem. 277 (2002) 1794-1799
128. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Båvenholm P., Rooyackers O., Zhou G., Williamson J.M., Ljunqvist O., Efendic S., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51 (2002) 2074-2081
129. Nagata D., Mogi M., and Walsh K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J. Biol. Chem. 278 (2003) 31000-31006
130. Natali A., Baldeweg S., Toschi E., Capaldo B., Barbaro D., Gastaldelli A., Yudkin J.S., and Ferrannini E. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 27 (2004) 1349-1357
131. Neunteufl T., Heher S., Katzenschlager R., Wolfl G., Kostner K., Maurer G., and Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am. J. Cardiol. 86 (2000) 207-210
132. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., Jure H., De Larochelliere R., Staniloae C.S., Mavromatis K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
133. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (2007) 2457-2471
134. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., and Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331 (1994) 1188-1193
135. Nyström T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm. Metab. Res. 40 (2008) 593-606
136. Nyström T., Gonon A.T., Sjöholm A., and Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul. Pept. 125 (2005) 173-177
137. Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., and Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287 (2004) E1209-1215
138. Nyström T., Nygren A., and Sjöholm A. Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. Am. J. Physiol. Endocrinol. Metab. 287 (2004) E919-925
139. Nyström T., Nygren A., and Sjöholm A. Persistent endothelial dysfunction is related to elevated C-reactive protein (CRP) levels in Type II diabetic patients after acute myocardial infarction. Clin. Sci. (Lond.) 108 (2005) 121-128
140. Nyström T., Nygren A., and Sjöholm A. Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction. Clin. Sci. (Lond.) 110 (2006) 673-681
141. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., and Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28 (1995) 103-117
142. Okouchi M., Okayama N., Omi H., Imaeda K., Fukutomi T., Nakamura A., and Itoh M. The antidiabetic agent, gliclazide, reduces high insulin-enhanced neutrophil-transendothelial migration through direct effects on the endothelium. Diabetes Metab. Res. Rev. 20 (2004) 232-238
143. Origin Trial I., Gerstein H., Yusuf S., Riddle M.C., Ryden L., and Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am. Heart J. 155 (2008) pp. 26-32, 32, e21-26
144. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
145. Özyazgan S., Kutluata N., Af S., Ozda S.B., and Akkan A.G. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 74 (2005) 119-126
146. Pagano P.J., Griswold M.C., Ravel D., and Cohen R.A. Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits. Diabetologia 41 (1998) 9-15
147. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X., Hu Z.X., Lin J., Xiao J.Z., Cao H.B., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20 (1997) 537-544
148. Park J.Y., Takahara N., Gabriele A., Chou E., Naruse K., Suzuma K., Yamauchi T., Ha S.W., Meier M., Rhodes C.J., et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 49 (2000) 1239-1248
149. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358 (2008) 2560-2572
150. Pfutzner A., Marx N., Lubben G., Langenfeld M., Walcher D., Konrad T., and Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J. Am. Coll. Cardiol. 45 (2005) 1925-1931
151. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27 (2004) 813-823
152. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
153. Pistrosch F., Passauer J., Fischer S., Fuecker K., Hanefeld M., and Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27 (2004) 484-490
154. Psaty B.M., and Furberg C.D. Rosiglitazone and cardiovascular risk. N. Engl. J. Med. 356 (2007) 2522-2524
155. Rakel A., Renier G., Roussin A., Buithieu J., Mamputu J.C., and Serri O. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes. Metab. 9 (2007) 127-129
156. Rask-Madsen C., Dominguez H., Ihlemann N., Hermann T., Kober L., and Torp-Pedersen C. Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108 (2003) 1815-1821
157. Rask-Madsen C., Ihlemann N., Krarup T., Christiansen E., Kober L., Nervil Kistorp C., and Torp-Pedersen C. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes 50 (2001) 2611-2618
158. Rask-Madsen C., and King G.L. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 46-56
159. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., and Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 (2005) 932-939
160. Renier G., Desfaits A.C., and Serri O. Gliclazide decreases low-density lipoprotein oxidation and monocyte adhesion to the endothelium. Metabolism 49 (2000) 17-22
161. Renier G., Mamputu J.C., and Serri O. Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells. Metabolism 52 (2003) 13-18
162. Richter G., Feddersen O., Wagner U., Barth P., Goke R., and Goke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am. J. Physiol. 265 (1993) L374-381
163. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336 (1997) 973-979
164. Riveline J.P., Danchin N., Ledru F., Varroud-Vial M., and Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab. 29 (2003) 207-222
165. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
166. Ryan M.J., Didion S.P., Mathur S., Faraci F.M., and Sigmund C.D. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 (2004) 661-666
167. Salani B., Repetto S., Cordera R., and Maggi D. Glimepiride activates eNOS with a mechanism Akt but not caveolin-1 dependent. Biochem. Biophys. Res. Commun. 335 (2005) 832-835
168. Salsburg D.S. The UGDP study. Jama 218 (1971) 1704-1705
169. Saltiel A.R., and Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 (2001) 799-806
170. Sartor G., Schersten B., Carlstrom S., Melander A., Norden A., and Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 29 (1980) 41-49
171. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
172. Scherrer U., Randin D., Vollenweider P., Vollenweider L., and Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J. Clin. Invest. 94 (1994) 2511-2515
173. Schulz E., Anter E., Zou M.H., and Keaney Jr. J.F. Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation 111 (2005) 3473-3480
174. Scott N.A., Jennings P.E., Brown J., and Belch J.J. Gliclazide: a general free radical scavenger. Eur. J. Pharmacol. 208 (1991) 175-177
175. Seeley R.J., Blake K., Rushing P.A., Benoit S., Eng J., Woods S.C., and D'Alessio D. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J. Neurosci. 20 (2000) 1616-1621
176. Seifarth C., Bergmann J., Holst J.J., Ritzel R., Schmiegel W., and Nauck M.A. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet. Med. 15 (1998) 485-491
177. Seltzer H.S. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 21 (1972) 976-979
178. Shetty G.K., Economides P.A., Horton E.S., Mantzoros C.S., and Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27 (2004) 2450-2457
179. Shimabukuro M., Higa N., Chinen I., Yamakawa K., and Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J. Clin. Endocrinol. Metab. 91 (2006) 837-842
180. Shimabukuro M., Higa N., and Takasu N. Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study. J. Diabetes Complications 20 (2006) 179-183
181. 2- imbalance in insulin-resistant rat aorta. Diabetes 48 (1999) 2437-2445
182. Shulman G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106 (2000) 171-176
183. Sidhu J.S., Cowan D., and Kaski J.C. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am. J. Cardiol. 94 (2004) 151-156
184. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
185. Sjöholm A., and Nyström T. Endothelial inflammation in insulin resistance. Lancet 365 (2005) 610-612
186. Sonne D.P., Engstrom T., and Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul. Pept. 146 (2008) 243-249
187. Stapleton D., Mitchelhill K.I., Gao G., Widmer J., Michell B.J., Teh T., House C.M., Fernandez C.S., Cox T., Witters L.A., et al. Mammalian AMP-activated protein kinase subfamily. J. Biol. Chem. 271 (1996) 611-614
188. Steinberg H.O., and Baron A.D. Insulin-mediated vasodilation: why one's physiology could be the other's pharmacology. Diabetologia 42 (1999) 493-495
189. Steinberg H.O., Brechtel G., Johnson A., Fineberg N., and Baron A.D. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J. Clin. Invest. 94 (1994) 1172-1179
190. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., and Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97 (1996) 2601-2610
191. Steinberg H.O., Tarshoby M., Monestel R., Hook G., Cronin J., Johnson A., Bayazeed B., and Baron A.D. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J. Clin. Invest. 100 (1997) 1230-1239
192. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.R., Ahima R.S., and Lazar M.A. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
193. Stroes E., Kastelein J., Cosentino F., Erkelens W., Wever R., Koomans H., Luscher T., and Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest. 99 (1997) 41-46
194. Stumvoll M., Nurjhan N., Perriello G., Dailey G., and Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333 (1995) 550-554
195. Sunden-Cullberg J., Nyström T., Lee M.L., Mullins G.E., Tokics L., Andersson J., Norrby-Teglund A., and Treutiger C.J. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit. Care Med. 35 (2007) 1536-1542
196. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes Jr. D.R., and Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000) 948-954
197. Szmitko P.E., Wang C.H., Weisel R.D., de Almeida J.R., Anderson T.J., and Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation 108 (2003) 1917-1923
198. Szmitko P.E., Wang C.H., Weisel R.D., Jeffries G.A., Anderson T.J., and Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: part II. Circulation 108 (2003) 2041-2048
199. Tesfamariam B., and Cohen R.A. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am. J. Physiol. 263 (1992) H321-326
200. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., Keinanen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344 (2001) 1343-1350
201. Tütüncü O., Nathanson D., Zangh F., Sjöholm A., Nyström T., and Zangh Q. Exendin-4 rapidly activates eNOS and protects human coronary artery endothelial cells against glucolipotoxicity. Diabetologia 51 (2008) S92
202. Ueba H., Kuroki M., Hashimoto S., Umemoto T., Yasu T., Ishikawa S.E., Saito M., and Kawakami M. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis 183 (2005) 35-39
203. Ueda S., Matsuoka H., Miyazaki H., Usui M., Okuda S., and Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J. Am. Coll. Cardiol. 35 (2000) 71-75
204. UK Prospective Diabetes Study (UKPDS) Group, 1998a. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865.
205. UK Prospective Diabetes Study (UKPDS) Group, 1998b. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853.
206. UK Prospective Diabetes Study (UKPDS) Group, 1999. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. Lancet 354, 617-621.
207. Vallejo S., Angulo J., Peiro C., Sanchez-Ferrer A., Cercas E., Llergo J.L., Nevado J., Sanchez-Ferrer C.F., and Rodriguez-Manas L. Prevention of endothelial dysfunction in streptozotocin-induced diabetic rats by gliclazide treatment. J. Diabetes Complications 14 (2000) 224-233
208. van de Laar F.A., and Lucassen P.L. No evidence for a reduction of myocardial infarctions by acarbose. Eur. Heart J. 25 (2004) 1179 author reply 1179-1180
209. Wang C.H., Ciliberti N., Li S.H., Szmitko P.E., Weisel R.D., Fedak P.W., Al-Omran M., Cherng W.J., Li R.K., Stanford W.L., et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109 (2004) 1392-1400
210. Wang T.D., Chen W.J., Cheng W.C., Lin J.W., Chen M.F., and Lee Y.T. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am. J. Cardiol. 98 (2006) 1057-1062
211. Wang T.D., Chen W.J., Lin J.W., Chen M.F., and Lee Y.T. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am. J. Cardiol. 93 (2004) 362-365
212. Wascher T.C., and Boes U. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients. Clin. Physiol. Funct. Imaging 25 (2005) 40-46
213. Wascher T.C., Schmoelzer I., Wiegratz A., Stuehlinger M., Mueller-Wieland D., Kotzka J., and Enderle M. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur. J. Clin. Invest. 35 (2005) 551-557
214. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., Tordo P., and Pritchard Jr. K.A. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 9220-9225
215. Vehkavaara S., Makimattila S., Schlenzka A., Vakkilainen J., Westerbacka J., and Yki-järvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 545-550
216. Verma S., and Anderson T.J. Fundamentals of endothelial function for the clinical cardiologist. Circulation 105 (2002) 546-549
217. Werner C., Kamani C.H., Gensch C., Bohm M., and Laufs U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 56 (2007) 2609-2615
218. Vicent D., Ilany J., Kondo T., Naruse K., Fisher S.J., Kisanuki Y.Y., Bursell S., Yanagisawa M., King G.L., and Kahn C.R. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest. 111 (2003) 1373-1380
219. Williams S.B., Goldfine A.B., Timimi F.K., Ting H.H., Roddy M.A., Simonson D.C., and Creager M.A. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97 (1998) 1695-1701
220. Vilsboll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., Courreges J.P., Verhoeven R., Buganova I., and Madsbad S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30 (2007) 1608-1610
221. Vitale C., Mercuro G., Cornoldi A., Fini M., Volterrani M., and Rosano G.M. Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. 258 (2005) 250-256
222. Wohrle J., Marx N., Koenig W., Hombach V., Kestler H.A., Hoher M., and Nusser T. Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. Clin. Res. Cardiol. 97 (2008) 726-733
223. Wu Y., Song P., Xu J., Zhang M., and Zou M.H. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J. Biol. Chem. 282 (2007) 9777-9788
224. 2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J. Biol. Chem. 273 (1998) 25804-25808
225. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., Hollenberg A.N., Baggio L., Saper C.B., Drucker D.J., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110 (2002) 43-52
226. Yamamoto K., Ohki R., Lee R.T., Ikeda U., and Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104 (2001) 1670-1675
227. Yki-järvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118
228. Yki-järvinen H., and Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology?. Diabetologia 41 (1998) 369-379
229. Yu M., Moreno C., Hoagland K.M., Dahly A., Ditter K., Mistry M., and Roman R.J. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens. 21 (2003) 1125-1135
230. Yudkin J.S., Panahloo A., Stehouwer C., Emeis J.J., Bulmer K., Mohamed-Ali V., and Denver A.E. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 43 (2000) 1099-1106
231. Zeng G., Nyström F.H., Ravichandran L.V., Cong L.N., Kirby M., Mostowski H., and Quon M.J. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101 (2000) 1539-1545
232. Zeng G., and Quon M.J. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest. 98 (1996) 894-898
233. Zethelius B., Byberg L., Hales C.N., Lithell H., and Berne C. Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation 105 (2002) 2153-2158
234. Zhang J., Xie Z., Dong Y., Wang S., Liu C., and Zou M.H. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J. Biol. Chem. 283 (2008) 27452-27461
235. Ziccardi P., Nappo F., Giugliano G., Esposito K., Marfella R., Cioffi M., D'Andrea F., Molinari A.M., and Giugliano D. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105 (2002) 804-809
236. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
237. Zimmet P.Z., and Alberti K.G. The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress. Lancet 350 Suppl 1 (1997) SI1-SI4